

# Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

## Author list:

Daniel Q. Huang<sup>1,2,3\*</sup>, Veeral Ajmera<sup>1,4\*</sup>, Christian Tomaszewski<sup>5</sup>, Andrew LaFree<sup>5</sup>, Ricki Bettencourt<sup>1</sup>, Wesley K Thompson<sup>6</sup>, Davey M. Smith<sup>7,8</sup>, Atul Malhotra<sup>9</sup>, Ravindra L Mehta<sup>10</sup>, Vaishal Tolia<sup>11</sup>, Jeffrey Yin<sup>12</sup>, Paul A Insel<sup>13,14</sup>, Stone Leachman<sup>1</sup>, Jinho Jung<sup>1</sup>, Summer Collier<sup>4</sup>, Lisa Richards<sup>1</sup>, Kristin Woods<sup>15</sup>, Maral Amangurbanova<sup>1</sup>, Archana Bhatt<sup>15</sup>, Xinlian Zhang<sup>16</sup>, Oana M. Penciu<sup>17</sup>, Stuart Zarich<sup>18</sup>, Tamrat Retta<sup>19</sup>, Michelle S. Harkins<sup>20</sup>, J. Pedro Teixeira<sup>20</sup>, Brian Chinnock<sup>21</sup>, Netanya S Utay<sup>22</sup>, Jordan E. Lake<sup>23</sup> and Rohit Loomba<sup>1,4,24†</sup>

1. NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, United States of America.
2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
3. Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
4. Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
5. Department of Emergency Medicine, University of California, San Diego and the El Centro Regional Medical Center, San Diego California, United States of America.
6. Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, United States of America.
7. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America
8. Veteran Affairs Medical Center, San Diego, California, United States of America.
9. Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
10. Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
11. Department of Emergency Medicine, University of California San Diego, La Jolla, California, United States of America.
12. Department of Pharmacy, University of California San Diego, La Jolla, California, United States of America.
13. Department of Pharmacology, University of California San Diego, La Jolla, California, United States of America.
14. Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, California, United States of America.
15. Clinical Translational Research Institute, University of California at San Diego, San Diego, California, United States of America.
16. Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, San Diego, California, United States of America.
17. Beverly Hospital, Montebello, California, United States of America.
18. Section of Cardiovascular Medicine, Yale New Haven Health Bridgeport Hospital, United States of America.
19. Department of Internal Medicine, Howard University, Washington, United States of America.
20. Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America.
21. Department of Emergency Medicine, University of California San Francisco Fresno, Fresno, California, United States of America.
22. Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.

23. Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, United States of America.
24. Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, San Diego, CA, United States of America.
- \*These authors share co-first authorship.

**†Corresponding Author:**

Rohit Loomba, MD, MHSc

Professor of Medicine

Director, NAFLD Research Center

University of California at San Diego

Altman Clinical and Translational Research Institute

9500 Gilman Drive La Jolla, CA, 92093-0887

**Supplemental Table 1. Scoring of toxicity for discontinuation**

<b>Adverse events</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>
<b>Allergic reaction</b>	Transient flushing or rash, Intervention not indicated	Intervention; Responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics); Prophylactic medications indicated for <=24 hrs	Prolonged (e.g., not rapidly responsive to symptomatic medication; Recurrence of symptoms following initial improvement; Hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates)	Life threatening consequences; Urgent intervention indicated	Death
<b>Anaphylaxis</b>			Symptomatic bronchospasm, with or without urticaria; Parenteral intervention indicated; Allergy-related edema/angioedema; Hypotension	Life-threatening consequences; Urgent intervention indicated	Death
<b>Hypotension</b>			SBP < 90 mm hg or DBP < 50 mm hg	Requiring vasopressor support	Death
<b>ALT (U/L)</b>	Baseline-1.5x baseline	>200 and > 1.5x baseline	>400 and > 2x baseline	401-800 and > 3x baseline	>800
<b>AST (U/L)</b>	Baseline-1.5x baseline	>200 and > 1.5x baseline	>400 and > 2x baseline	401-800 and > 3x baseline	>800
<b>Total Bilirubin (mg/dL)</b>	0.1 to 1	1.1 to 2 and direct bilirubin >0.5	2 to 5 and direct bilirubin > 1	5.1 to 10	>10
<b>Potassium (mg/dL)</b>	5.1-5.3	> 5.3-5.5	> 5.5- 6.0 Investigator can assess for possible hemolysis	> 6.0	Death
<b>Creatinine (mg/dL)</b>	Creatinine level increase of >0.3 mg/dL; Creatinine 1- 1.5 x above baseline	Creatinine 1.5 - 2x above baseline	Creatinine >2x baseline or >2.0 mg/dL; Hospitalization indicated	Life-threatening consequences; Dialysis indicated	Death

Scoring of toxicity from the CTC Version 4.0, with modifications

**Supplemental Table 2.** Concomitant therapy for COVID-19, by treatment allocation

	<b>Ramipril</b> (N=79)	<b>Placebo</b> (N=35)
<b>Concomitant therapy, n (%)</b>		
Azithromycin	25 (32)	8 (23)
Chloroquine	0 (0)	0 (0)
Corticosteroid	20 (25)	5 (14)
Remdesivir	21 (27)	6 (17)
Monoclonal antibody	1(1)	0 (0)